Journal of Arrhythmia (Oct 2024)

Distribution of anti‐factor Xa activity in patients with nonvalvular atrial fibrillation receiving 15 mg dose of edoxaban

  • Shotaro Hiramatsu,
  • Hiroyuki Osanai,
  • Yuichiro Sakai,
  • Yoshiki Sogo,
  • Yuki Tanaka,
  • Hikari Matsumoto,
  • Shun Miyamoto,
  • Kensuke Tagahara,
  • Kenji Arai,
  • Takashi Watanabe,
  • Yusuke Sakamoto,
  • Teruhiro Sakaguchi,
  • Shioh Oguchi,
  • Takahiro Kanbara,
  • Yoshihito Nakashima,
  • Hiroshi Asano,
  • Masayoshi Ajioka

DOI
https://doi.org/10.1002/joa3.13139
Journal volume & issue
Vol. 40, no. 5
pp. 1126 – 1130

Abstract

Read online

Abstract Background The distribution of anti‐factor Xa activity (AXA) in patients with nonvalvular atrial fibrillation (NVAF) taking edoxaban 15 mg has not been fully elucidated. Methods and Results The trough and peak AXA were measured in 19 NVAF patients taking edoxaban 15 mg. We compared these results with those in patients taking edoxaban 30 mg. The peak AXA differed significantly between the 15 mg and the 30 mg groups (0.74 ± 0.40 IU/mL vs. 1.25 ± 0.48 IU/mL, respectively; p < 0.0001). Conclusions Peak but trough AXA in the patients receiving edoxaban 15 mg were significantly lower than those in patients receiving edoxaban 30 mg.

Keywords